Researcher.Life Logo

BMC Pulmonary Medicine : Impact Factor & More

eISSN: 1471-2466pISSN: 1471-2466
JournalOpen Access

Key Metrics

CiteScore
4.2
Impact Factor
< 5
Scite Index
0.86 5-Year SI
SJR
Q2Pulmonary and Respiratory Medicine
SNIP
1.23
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on BMC Pulmonary Medicine

BMC Pulmonary Medicine Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher BMC
Language English
Frequency Continuous publication
Article Processing ChargesEUR 2290 | USD 2790 | GBP 1990
Publication Time23
Editorial Review ProcessOpen peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2000
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 23
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessOpen peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC0
OA statementVisit website
View less

Planning to publish in BMC Pulmonary Medicine ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in BMC Pulmonary Medicine

Real-world treatment and healthcare resource utilization patterns among patients with advanced non-small cell lung cancer treated with amivantamab: a retrospective study using insurance claims data.
  • 14 May 2026
  • BMC pulmonary medicine
Identification of risk factors and development of a predictive model for early renal impairment in patients with obstructive sleep apnea-hypopnea syndrome.
  • 13 May 2026
  • BMC pulmonary medicine
Factors associated with bronchiectasis in Sri Lanka: evidence from a multicenter case-control study in the Colombo District.
  • 13 May 2026
  • BMC pulmonary medicine
Remdesivir for the treatment of children hospitalized with COVID-19: a systematic review and meta-analysis.
  • 13 May 2026
  • BMC pulmonary medicine
Anti-Ro-52 antibody is a risk factor for recurrence in interstitial lung disease with positive anti-aminoacyl tRNA synthetase antibody: a single-center, retrospective observational study.
  • 12 May 2026
  • BMC pulmonary medicine
Is obstructive sleep apnea a driver of cancer and chronic disease risk? A real-world analysis of over 3million patients.
  • 12 May 2026
  • BMC pulmonary medicine
Real-world treatment and healthcare resource utilization patterns among patients with advanced non-small cell lung cancer treated with amivantamab: a retrospective study using insurance claims data.
  • 14 May 2026
  • BMC pulmonary medicine
Identification of risk factors and development of a predictive model for early renal impairment in patients with obstructive sleep apnea-hypopnea syndrome.
  • 13 May 2026
  • BMC pulmonary medicine
Factors associated with bronchiectasis in Sri Lanka: evidence from a multicenter case-control study in the Colombo District.
  • 13 May 2026
  • BMC pulmonary medicine
Remdesivir for the treatment of children hospitalized with COVID-19: a systematic review and meta-analysis.
  • 13 May 2026
  • BMC pulmonary medicine
Anti-Ro-52 antibody is a risk factor for recurrence in interstitial lung disease with positive anti-aminoacyl tRNA synthetase antibody: a single-center, retrospective observational study.
  • 12 May 2026
  • BMC pulmonary medicine
Is obstructive sleep apnea a driver of cancer and chronic disease risk? A real-world analysis of over 3million patients.
  • 12 May 2026
  • BMC pulmonary medicine

FAQs on BMC Pulmonary Medicine